Capital Raising

COMPLETED

Oscar Resources Limited

Iron Ore company utilising breakthrough technology

INDUSTRY

Medical, Technology

RAISING

A$1.116M

PRE-MONEY VALUATION

A$8.9M

OFFER PRICE

A$0.171

Investment Highlights

Company Overview

Products & Services

Additional Information

Team

Transaction Summary
Biosignals Diagnostics

Raising A$1.116M

A$0.171 per share

Investment Highlights

Biosignal monitoring company

Prevent, diagnose, and change outcomes for heart disease & stroke

ECGme device provides cost effective & real time solutions

Precision Healthcare

Company Overview

Heart disease remains the biggest killer in the world

death rates are estimated to double in the next 20 years

Biosignals Diagnostics provides solutions

Several global markets offering tailored solutions based on unmet needs or improved standard of care

ISV partner agreement with Oracle

signed on 5th April 2022

Demonstrations of the ECGme device

completed across twelve private meetings at the AusMedtech2022 conference

Products & Services

Biosignals Diagnostics offers solutions that target unmet clinical needs or improved standard of care in heart disease, with verified customers and markets.

Biosignals Diagnostics is a biosignal monitoring company, that addresses heart disease problems by integrating biometric data from specially designed, easily used devices and other sources such as imaging and genetics.

Product Suite

ECGME

  • Small easy to use the device (the size of a credit card), fits in your pocket and when held with fingers on the sensors analyses real-time ECG signals
  • Point-in-time ECG snapshot configurable for up to 10 minutes monitoring duration
  • Converts to a 2 electrode 24hr on-body monitor for clinical use
  • A TGA-approved Class 2a medical device
  • Available July 2022

Transaction Overview

Raising A$1.116M at A$0.171 per share, with a pre-money valuation of A$8.9M,

6,521,739 shares on offer

Use of funds

20%

ECGme Deployment

30%

Platform Software Development

30%

Marketing / Sales

20%

3 Lead ECG3me Development

Team

Management

Richard Rendell

Managing Director & Founder

Christopher Pendlebury

Chief Science Officer

Hayden Pitout

Chief Technical Officer

Kevin Hollingsworth

Company Secretary

Lexie Qin

Head of Product Engineering

Renee Ge

AI & Data Sciences Engineering

Stephan G Foy – MB ChB MD

Consulting Cardiologist & Clinical Advisor

Want to learn more?

Fill in the expression of interest form below

window.lintrk('track', { conversion_id: 14400772 });